Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Goodwill (2016 - 2026)

Summit Therapeutics filings provide 13 years of Goodwill readings, the most recent being $2.0 million for Q1 2026.

  • Quarterly Goodwill rose 2.18% to $2.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Mar 2026, up 2.18% year-over-year, with the annual reading at $2.0 million for FY2025, 7.35% up from the prior year.
  • Goodwill hit $2.0 million in Q1 2026 for Summit Therapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Goodwill topped out at $2.0 million in Q2 2025 and bottomed at $1.7 million in Q3 2022.
  • Average Goodwill over 5 years is $1.9 million, with a median of $1.9 million recorded in 2023.
  • The largest annual shift saw Goodwill fell 17.25% in 2022 before it increased 9.76% in 2024.
  • Summit Therapeutics' Goodwill stood at $1.8 million in 2022, then grew by 5.28% to $1.9 million in 2023, then decreased by 1.53% to $1.9 million in 2024, then increased by 7.35% to $2.0 million in 2025, then fell by 1.8% to $2.0 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Goodwill are $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025).